Most studies on neuropeptides have been focused on peptides that are synthesized in the secretory pathway and released in a regulated manner when the cell is stimulated. We now refer to these molecules as "classical neuropeptides," by analogy to the term "classical neurotransmitters" that is often used to describe molecules such as acetylcholine and dopamine which are stored in vesicles and secreted on demand, and distinct from "non-classical neurotransmitters" such as NO and anandamide that are synthesized in a regulated manner in the cytosol and then immediately secreted from the cell. Several lines of evidence point to a new group of signaling molecules, which we refer to as "non-classical neuropeptides." These molecules are not produced in the secretory pathway by the conventional peptide processing enzymes, but are instead derived from cytosolic proteins by an unknown mechanism. There have been reports of bioactive peptides that are derived from cytosolic proteins, but the key experiments to establish these as non-classical neuropeptides have not yet been performed. We recently identified a number of hemoglobin-derived peptides in mouse brain, and several of these peptides (N-terminally extended forms of a peptide named "hemopressin") were found to be agonists of CB1 cannabinoid receptors. These hemopressin peptides are present in mouse brain at levels comparable to many of the abundant neuropeptides, based on their signal strength in mass spectrometry, and are secreted from brain slices. Furthermore, we have found that hemoglobin mRNA is present in neuronal cultures, and recent reports from two other groups have shown the presence of hemoglobin mRNA and protein in neurons. The critical studies to establish hemopressin as a non-classical neuropeptide will be performed.
Aim 1 will examine the enzymatic pathway by which hemopressin peptides are generated and degraded.
Aim 2 will examine the mechanism by which hemopressin peptides are secreted from brain cells.
Aim 3 will explore the mechanism(s) by which hemopressin peptides are regulated, either at the level of synthesis or secretion. These studies will contribute to a better understanding of the role of non-classical peptides in general, and on the hemopressin peptides in particular, which due to their activity at CB1 cannabinoid are relevant to drugs of abuse.

Public Health Relevance

Neuropeptides function in cell-cell signaling and are produced in the secretory pathway, stored in vesicles, and released in a regulated manner when the cell is stimulated. Several lines of evidence point to a new type of neuropeptide, or non-classical neuropeptide, that is not produced in the secretory pathway by the conventional neuropeptide processing enzymes, but is instead derived from cytosolic proteins. The critical studies to establish if novel cannabinoid receptor agonist peptides (named the hemopressins) represent non-classical neuropeptides are described in this application.

Agency
National Institute of Health (NIH)
Type
Research Project (R01)
Project #
5R01DA004494-27
Application #
8653940
Study Section
Molecular Neuropharmacology and Signaling Study Section (MNPS)
Program Officer
Rapaka, Rao
Project Start
Project End
Budget Start
Budget End
Support Year
27
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Albert Einstein College of Medicine
Department
Pharmacology
Type
Schools of Medicine
DUNS #
City
Bronx
State
NY
Country
United States
Zip Code
10461
Lopes, Mark William; Sapio, Matthew R; Leal, Rodrigo B et al. (2016) Knockdown of Carboxypeptidase A6 in Zebrafish Larvae Reduces Response to Seizure-Inducing Drugs and Causes Changes in the Level of mRNAs Encoding Signaling Molecules. PLoS One 11:e0152905
Gomes, Ivone; Bobeck, Erin N; Margolis, Elyssa B et al. (2016) Identification of GPR83 as the receptor for the neuroendocrine peptide PEN. Sci Signal 9:ra43
Dasgupta, Sayani; Fishman, Michael A; Mahallati, Hana et al. (2015) Reduced Levels of Proteasome Products in a Mouse Striatal Cell Model of Huntington's Disease. PLoS One 10:e0145333
Fricker, Lloyd D (2015) Limitations of Mass Spectrometry-Based Peptidomic Approaches. J Am Soc Mass Spectrom 26:1981-91
Sapio, Matthew R; Vessaz, Monique; Thomas, Pierre et al. (2015) Novel carboxypeptidase A6 (CPA6) mutations identified in patients with juvenile myoclonic and generalized epilepsy. PLoS One 10:e0123180
Dasgupta, Sayani; Castro, Leandro M; Dulman, Russell et al. (2014) Proteasome inhibitors alter levels of intracellular peptides in HEK293T and SH-SY5Y cells. PLoS One 9:e103604
Wardman, Jonathan H; Fricker, Lloyd D (2014) ProSAAS-derived peptides are differentially processed and sorted in mouse brain and AtT-20 cells. PLoS One 9:e104232
Sapio, Matthew R; Fricker, Lloyd D (2014) Carboxypeptidases in disease: insights from peptidomic studies. Proteomics Clin Appl 8:327-37
Berezniuk, Iryna; Lyons, Peter J; Sironi, Juan J et al. (2013) Cytosolic carboxypeptidase 5 removes α- and γ-linked glutamates from tubulin. J Biol Chem 288:30445-53
Rodriguiz, Ramona M; Wilkins, John J; Creson, Thomas K et al. (2013) Emergence of anxiety-like behaviours in depressive-like Cpe(fat/fat) mice. Int J Neuropsychopharmacol 16:1623-34

Showing the most recent 10 out of 121 publications